Thermo Fisher Scientific

TMO

Market cap $198B

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher's PPD™ clinical research business will gain enterprise-level access to HealthVerity's TaXOnomy® claims dataset, representing more than 270 million de-identified pa.

TMO teams up with PRECISE on a major proteomics study, expanding its role in large biobank projects and precision medicine initiatives.

The Iran conflict has given investors a reason to sell just about everything. The Dow is in correction territory.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced a strategic collaboration with Precision Health Research, Singapore (PRECISE) to advance the PRECISE-SG100K study, one of the region's most ambitious and diverse population-scale biobank initiatives. The collaboration reflects growing investments from national population studies looking to harness proteomics to drive insight into real-time disease biology for applicat.

Thermo Fisher's shares have fallen more than 15% so far this year. The medical instrument company has grown strategically through acquisitions.

Thermo Fisher unveils the Gibco CTS Compleo system to automate cell therapy manufacturing, targeting efficiency gains and consistency as demand in the fast-growing market rises.

The April 2026 Top 25 High Growth Dividend Stocks list targets quality companies trading below intrinsic value, averaging a 1.52% yield and 17.7% five-year dividend growth. Screened stocks appear ~34% undervalued by dividend yield theory, with an estimated +21% annualized long-term return potential. MSCI, WING, ZTS, INTU, and MSFT stand out for attractive valuations, robust dividend growth, and strong projected EPS growth.

Thermo Fisher may gain as it unveils its Gibco CHOvantage GS CLD Kit to speed biologics development, cut costs and boost cell culture growth.